Evidence Regarding Pharmacogenetics in Pain Management and Cancer
Abstract Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2023-03, Vol.28 (3), p.189-192 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 192 |
|---|---|
| container_issue | 3 |
| container_start_page | 189 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 28 |
| creator | Smith, D Max Figg, William D |
| description | Abstract
Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.
Highlighting a recently published trial on COMT genotype and opioid dose requirements, this commentary describes the potential role for COMT and other genes (e.g., CYP2D6) on opioid therapy and current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics. |
| doi_str_mv | 10.1093/oncolo/oyac277 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10020807</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779838458</galeid><oup_id>10.1093/oncolo/oyac277</oup_id><sourcerecordid>A779838458</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-83d59d43639dbf04a9e586072bed83801fab9548ef506b998850e4c9f216a1033</originalsourceid><addsrcrecordid>eNqFkcFLHDEUxkNpqVZ79SgDvbSH0WSSmSSnsizWFhRFFHoLb5I3Y8pMsk12Bf_7RnaVFoQSSB7J7318Lx8hR4yeMKr5aQw2TvE0PoJtpHxD9lkrdC00_fm21FTxWrJW75EPOf-itJS8eU_2eCeZog3dJ4uzB-8wWKxucITkfBir63tIM9g4YsC1t7nyobqGsl1CgBFnDOsKgquWUPrSIXk3wJTx4-48IHffzm6X3-uLq_Mfy8VFbYWQ61px12oneMe16wcqQGOrOiqbHp3iirIBet0KhUNLu15rpVqKwuqhYR0wyvkB-brVXW36GZ0tLhJMZpX8DOnRRPDm35fg780YHwyjZVJFZVH4vFNI8fcG89rMPlucJggYN9mUD2Scs-KwoJ-26AgTGh-GWCTtE24WUupiWLSqUCevUGU5nL2NAQdf7l9rsCnmnHB4sc-oecrTbPM0uzxLw_HfQ7_gzwEW4MsWiJvV_8T-AG11qxk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771331639</pqid></control><display><type>article</type><title>Evidence Regarding Pharmacogenetics in Pain Management and Cancer</title><source>Oxford Journals Open Access Collection</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Smith, D Max ; Figg, William D</creator><creatorcontrib>Smith, D Max ; Figg, William D</creatorcontrib><description>Abstract
Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.
Highlighting a recently published trial on COMT genotype and opioid dose requirements, this commentary describes the potential role for COMT and other genes (e.g., CYP2D6) on opioid therapy and current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyac277</identifier><identifier>PMID: 36718020</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Analgesics, Opioid - therapeutic use ; Analysis ; Cancer pain ; Cancer Pain - drug therapy ; Cancer Pain - genetics ; Care and treatment ; Catechol O-Methyltransferase - genetics ; Catechol O-Methyltransferase - therapeutic use ; Commentaries ; Cytochrome P-450 CYP2D6 - genetics ; Cytochrome P-450 CYP2D6 - therapeutic use ; Evaluation ; Evidence-based medicine ; Genetic aspects ; Genotype ; Humans ; Morphine - therapeutic use ; Neoplasms - drug therapy ; Neoplasms - genetics ; Oxycodone - therapeutic use ; Pain Management ; Pharmacogenetics</subject><ispartof>The oncologist (Dayton, Ohio), 2023-03, Vol.28 (3), p.189-192</ispartof><rights>The Author(s) 2023. Published by Oxford University Press. 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press.</rights><rights>COPYRIGHT 2023 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c447t-83d59d43639dbf04a9e586072bed83801fab9548ef506b998850e4c9f216a1033</cites><orcidid>0000-0002-5875-2606 ; 0000-0003-3667-2936</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020807/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020807/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1604,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36718020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, D Max</creatorcontrib><creatorcontrib>Figg, William D</creatorcontrib><title>Evidence Regarding Pharmacogenetics in Pain Management and Cancer</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Abstract
Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.
Highlighting a recently published trial on COMT genotype and opioid dose requirements, this commentary describes the potential role for COMT and other genes (e.g., CYP2D6) on opioid therapy and current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.</description><subject>Analgesics, Opioid - therapeutic use</subject><subject>Analysis</subject><subject>Cancer pain</subject><subject>Cancer Pain - drug therapy</subject><subject>Cancer Pain - genetics</subject><subject>Care and treatment</subject><subject>Catechol O-Methyltransferase - genetics</subject><subject>Catechol O-Methyltransferase - therapeutic use</subject><subject>Commentaries</subject><subject>Cytochrome P-450 CYP2D6 - genetics</subject><subject>Cytochrome P-450 CYP2D6 - therapeutic use</subject><subject>Evaluation</subject><subject>Evidence-based medicine</subject><subject>Genetic aspects</subject><subject>Genotype</subject><subject>Humans</subject><subject>Morphine - therapeutic use</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Oxycodone - therapeutic use</subject><subject>Pain Management</subject><subject>Pharmacogenetics</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqFkcFLHDEUxkNpqVZ79SgDvbSH0WSSmSSnsizWFhRFFHoLb5I3Y8pMsk12Bf_7RnaVFoQSSB7J7318Lx8hR4yeMKr5aQw2TvE0PoJtpHxD9lkrdC00_fm21FTxWrJW75EPOf-itJS8eU_2eCeZog3dJ4uzB-8wWKxucITkfBir63tIM9g4YsC1t7nyobqGsl1CgBFnDOsKgquWUPrSIXk3wJTx4-48IHffzm6X3-uLq_Mfy8VFbYWQ61px12oneMe16wcqQGOrOiqbHp3iirIBet0KhUNLu15rpVqKwuqhYR0wyvkB-brVXW36GZ0tLhJMZpX8DOnRRPDm35fg780YHwyjZVJFZVH4vFNI8fcG89rMPlucJggYN9mUD2Scs-KwoJ-26AgTGh-GWCTtE24WUupiWLSqUCevUGU5nL2NAQdf7l9rsCnmnHB4sc-oecrTbPM0uzxLw_HfQ7_gzwEW4MsWiJvV_8T-AG11qxk</recordid><startdate>20230317</startdate><enddate>20230317</enddate><creator>Smith, D Max</creator><creator>Figg, William D</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5875-2606</orcidid><orcidid>https://orcid.org/0000-0003-3667-2936</orcidid></search><sort><creationdate>20230317</creationdate><title>Evidence Regarding Pharmacogenetics in Pain Management and Cancer</title><author>Smith, D Max ; Figg, William D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-83d59d43639dbf04a9e586072bed83801fab9548ef506b998850e4c9f216a1033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analgesics, Opioid - therapeutic use</topic><topic>Analysis</topic><topic>Cancer pain</topic><topic>Cancer Pain - drug therapy</topic><topic>Cancer Pain - genetics</topic><topic>Care and treatment</topic><topic>Catechol O-Methyltransferase - genetics</topic><topic>Catechol O-Methyltransferase - therapeutic use</topic><topic>Commentaries</topic><topic>Cytochrome P-450 CYP2D6 - genetics</topic><topic>Cytochrome P-450 CYP2D6 - therapeutic use</topic><topic>Evaluation</topic><topic>Evidence-based medicine</topic><topic>Genetic aspects</topic><topic>Genotype</topic><topic>Humans</topic><topic>Morphine - therapeutic use</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Oxycodone - therapeutic use</topic><topic>Pain Management</topic><topic>Pharmacogenetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, D Max</creatorcontrib><creatorcontrib>Figg, William D</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, D Max</au><au>Figg, William D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence Regarding Pharmacogenetics in Pain Management and Cancer</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2023-03-17</date><risdate>2023</risdate><volume>28</volume><issue>3</issue><spage>189</spage><epage>192</epage><pages>189-192</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Abstract
Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.
Highlighting a recently published trial on COMT genotype and opioid dose requirements, this commentary describes the potential role for COMT and other genes (e.g., CYP2D6) on opioid therapy and current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>36718020</pmid><doi>10.1093/oncolo/oyac277</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-5875-2606</orcidid><orcidid>https://orcid.org/0000-0003-3667-2936</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2023-03, Vol.28 (3), p.189-192 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10020807 |
| source | Oxford Journals Open Access Collection; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analgesics, Opioid - therapeutic use Analysis Cancer pain Cancer Pain - drug therapy Cancer Pain - genetics Care and treatment Catechol O-Methyltransferase - genetics Catechol O-Methyltransferase - therapeutic use Commentaries Cytochrome P-450 CYP2D6 - genetics Cytochrome P-450 CYP2D6 - therapeutic use Evaluation Evidence-based medicine Genetic aspects Genotype Humans Morphine - therapeutic use Neoplasms - drug therapy Neoplasms - genetics Oxycodone - therapeutic use Pain Management Pharmacogenetics |
| title | Evidence Regarding Pharmacogenetics in Pain Management and Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A03%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20Regarding%20Pharmacogenetics%20in%20Pain%20Management%20and%20Cancer&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Smith,%20D%20Max&rft.date=2023-03-17&rft.volume=28&rft.issue=3&rft.spage=189&rft.epage=192&rft.pages=189-192&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyac277&rft_dat=%3Cgale_pubme%3EA779838458%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771331639&rft_id=info:pmid/36718020&rft_galeid=A779838458&rft_oup_id=10.1093/oncolo/oyac277&rfr_iscdi=true |